{"entity":{"id":"nct07071844","kind":"trial","name":"BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients","aka":["BETWEEN"],"tldr":"A phase 2 trial of trifluridine/tipiracil and bevacizumab (glioblastoma use) in colorectal cancer, run by GERCOR - Multidisciplinary Oncology Cooperative Group, not yet recruiting.","summary":"BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients is a phase 2, randomised interventional study registered as NCT07071844 by GERCOR - Multidisciplinary Oncology Cooperative Group, with a registry enrolment figure of 162 participants, started 2025-09 and due to reach its primary completion in 2028-12. Interventions recorded: Trifluridine/tipiracil; Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: The occurrence of at least one grade 3-4 neutropenia. Colorectal eligibility wording from the registry: \"Histologically proven colorectal adenocarcinoma,\". Sites: France. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07071844","url":"https://clinicaltrials.gov/study/NCT07071844"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["trifluridine-tipiracil","bevacizumab-glioma"],"companies":["servier","gercor"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07071844","phase":"2","setting":"BEvacizumab Plus Trifluridine/Tipiracil in a Bi-WEEkly Administration to Reduce Grade 3-4 Neutropenia in Patients With mCRC: A Prospective, Multicenter, Comparative, Randomized GERCOR G-124 BETWEEN Phase II Study","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","enrolled":162,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07071844/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/"}],"company":[{"id":"gercor","kind":"company","name":"GERCOR","route":"/companies/gercor/"},{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}